BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 28385199)

  • 1. Neuromyelitis Spectrum Disorders.
    Weinshenker BG; Wingerchuk DM
    Mayo Clin Proc; 2017 Apr; 92(4):663-679. PubMed ID: 28385199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
    Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
    Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical concept, etiology and pathology of neuromyelitis optica].
    Kurosawa K; Fujihara K
    Nihon Rinsho; 2014 Nov; 72(11):1897-902. PubMed ID: 25518368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
    Alves Do Rego C; Collongues N
    Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder.
    You Y; Zhu L; Zhang T; Shen T; Fontes A; Yiannikas C; Parratt J; Barton J; Schulz A; Gupta V; Barnett MH; Fraser CL; Gillies M; Graham SL; Klistorner A
    Ophthalmology; 2019 Jun; 126(6):801-810. PubMed ID: 30711604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
    Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW
    Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuromyelitis optica].
    Ferrán C; Pedemonte V; Turcatti E; González G
    Medicina (B Aires); 2019; 79 Suppl 3():60-65. PubMed ID: 31603846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions.
    Popescu BF; Guo Y; Jentoft ME; Parisi JE; Lennon VA; Pittock SJ; Weinshenker BG; Wingerchuk DM; Giannini C; Metz I; Brück W; Shuster EA; Carter J; Boyd CD; Clardy SL; Cohen BA; Lucchinetti CF
    Neurology; 2015 Jan; 84(2):148-58. PubMed ID: 25503621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What You Need to Know About AQP4, MOG, and NMOSD.
    Prasad S; Chen J
    Semin Neurol; 2019 Dec; 39(6):718-731. PubMed ID: 31847043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.
    Sato DK; Callegaro D; Lana-Peixoto MA; Nakashima I; Fujihara K
    Arq Neuropsiquiatr; 2014 Jun; 72(6):445-50. PubMed ID: 24964112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification].
    Aktas O; Kümpfel T
    Nervenarzt; 2021 Apr; 92(4):307-316. PubMed ID: 33728474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central nervous system neuroinflammatory disorders in Asian/Pacific regions.
    Kim SH; Kim HJ
    Curr Opin Neurol; 2016 Jun; 29(3):372-80. PubMed ID: 27128108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnostic criteria for neuromyelitisoptica spectrum disorders].
    Belova AN; Bojko AN; Belova EM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):32-40. PubMed ID: 27070359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromyelitis optica spectrum disorders.
    Paul S; Mondal GP; Bhattacharyya R; Ghosh KC; Bhat IA
    J Neurol Sci; 2021 Jan; 420():117225. PubMed ID: 33272591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.
    Takai Y; Misu T; Suzuki H; Takahashi T; Okada H; Tanaka S; Okita K; Sasou S; Watanabe M; Namatame C; Matsumoto Y; Ono H; Kaneko K; Nishiyama S; Kuroda H; Nakashima I; Lassmann H; Fujihara K; Itoyama Y; Aoki M
    Brain; 2021 Sep; 144(8):2401-2415. PubMed ID: 33711152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis Optica Spectrum Disorders.
    Costello F
    Continuum (Minneap Minn); 2022 Aug; 28(4):1131-1170. PubMed ID: 35938660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and radiologic approach to 'typical' versus antibody-related optic neuritis.
    Caron-Cantin M; Cestari DM; Fortin E
    Curr Opin Ophthalmol; 2019 Nov; 30(6):412-417. PubMed ID: 31503075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
    Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Neuromyelitis Optica Spectrum Disorders.
    Chan KH; Lee CY
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiculopathy in neuromyelitis optica. How does anti-AQP4 Ab involve PNS?
    Kim S; Park J; Kwon BS; Park JW; Lee HJ; Choi JH; Nam K
    Mult Scler Relat Disord; 2017 Nov; 18():77-81. PubMed ID: 29141825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.